methyl 2-(4-bromophenyl)oxazole-4-carboxylate | 1239589-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 2-(4-bromophenyl)oxazole-4-carboxylate
• 英文别名: Methyl2-(4-bromophenyl)-1,3-oxazole-4-carboxylate；methyl 2-(4-bromophenyl)-1,3-oxazole-4-carboxylate
• CAS: 1239589-17-3
• 化学式: C₁₁H₈BrNO₃
• 分子量: 282.093
• InChiKey: DJJFPEYUVDZYOG-UHFFFAOYSA-N

物化性质

• 熔点：
  154-156 °C
• 沸点：
  369.3±48.0 °C(Predicted)
• 密度：
  1.526±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-bromophenyl)oxazole-4-carboxylate 在 lithium aluminium tetrahydride 、 氯化亚砜 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 6.0h， 生成 (1-((2-(4-bromophenyl)oxazol-4-yl)methyl)piperidin-4-yl)(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanone
  参考文献：
  名称：

  Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

  摘要：

  A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi-and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.072
• 作为产物：
  描述：

  3-(4-bromophenyl)-5-methoxyisoxazole-4-carbaldehyde 在 iron(II) chloride tetrahydrate 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以57%的产率得到methyl 2-(4-bromophenyl)oxazole-4-carboxylate
  参考文献：
  名称：

  通过受控的异恶唑-Azirine-异恶唑/异恶唑异构化合成异恶唑和恶唑-4-羧酸衍生物。

  摘要：

  报道了通过多米诺骨牌异恶唑-异恶唑异构化的首次合成异恶唑-4-羧酸衍生物。Fe（II）催化的4-酰基-5-甲氧基-/ 5-氨基异恶唑（二恶烷，105°C）的异构化导致形成高收率的异恶唑-4-羧酸酯和酰胺。在相同的反应条件下，4-甲酰基-5-甲氧基异恶唑生成恶唑-4-羧酸甲酯。Fe（II）在较温和的条件下（MeCN，50°C）催化4-酰基-5-甲氧基异恶唑的异构化反应可以制备瞬时的2-酰基-2-（甲氧基羰基）-2H-叠氮基。在催化条件下（二恶烷，105°C）或在非催化热解条件下（邻二氯苯，170°C），叠氮化物定量异构化为异恶唑。

  DOI：

  10.1021/acs.joc.9b02536

文献信息

• Cobalt-Catalyzed Cross-Dehydrogenative C(sp² )−C(sp³ ) Coupling of Oxazole/Thiazole with Ether or Cycloalkane
  作者：Xiaojiao Wang、Bowen Lei、Lifang Ma、Lisi Zhu、Xinyue Zhang、Hao Zuo、Dailin Zhuang、Ziyuan Li

  DOI：10.1002/asia.201701258

  日期：2017.11.2

  Direct C5‐alkylation of oxazole/thiazole with ether or cycloalkane has been achieved through a cobalt‐catalyzed cross‐dehydrogenative coupling (CDC) process in moderate to good yields. This transformation represents the first C(sp2)−C(sp3) cross‐coupling at the C5‐position of the oxazole/thiazole via double C−H bond cleavages. Various functional groups on oxazole/thiazole substrates, as well as water

  通过钴催化的交叉脱氢偶联（CDC）工艺，恶唑/噻唑与醚或环烷烃直接进行C5-烷基化反应，产率中等至良好。这种转变代表通过双CH键断裂在恶唑/噻唑的C5位上的第一个C（sp 2）-C（sp 3）交叉偶联。简明实用的方案很好地耐受了恶唑/噻唑底物上的各种官能团，以及水和空气，构成了直接进入具有重要医学意义的杂环的方法。还提出了涉及激进过程的初步机制。
• DDQ-promoted direct C5-alkylation of oxazoles with alkylboronic acids via palladium-catalysed C–H bond activation
  作者：Bowen Lei、Xiaojiao Wang、Lifang Ma、Huixuan Jiao、Lisi Zhu、Ziyuan Li

  DOI：10.1039/c7ob01083d

  日期：——

  A novel and concise C5-alkylation of oxazole using alkylboronic acids as the alkyl donor via Pd(II)-catalysed C-H bond activation has been achieved in moderate to good yields with satisfactory functional group tolerance. Instead of commonly used BQ as a key promoter, DDQ was discovered to be a better additive that significantly promoted this alkylation. This efficient and advanced method represents

  使用烷基硼酸作为烷基供体通过Pd（II）催化的CH键活化，实现了新颖简明的恶唑C5-烷基化反应，具有中等至良好的收率，并具有令人满意的官能团耐受性。发现DDQ替代了通常使用的BQ作为关键促进剂，它是一种显着促进这种烷基化的更好的添加剂。这种高效，先进的方法代表了在恶唑的C5位上的第一个C（sp2）-C（sp3）交叉偶联反应，由于其在含恶唑生物活性分子的后期功能化中的潜在应用而特别引人注目。
• Iron-catalyzed C(5)−H Imidation of Azole with <i>N</i> -Fluorobenzenesulfonimide
  作者：Xiaojiao Wang、Bowen Lei、Lifang Ma、Huixuan Jiao、Wenhua Xing、Jiaming Chen、Ziyuan Li

  DOI：10.1002/adsc.201701124

  日期：2017.12.19

  An iron(II)‐catalyzed direct imidation of oxazole and thiazole with N‐fluorobenzenesulfonimide (NFSI) through C(5)−H bond cleavage is disclosed, providing C5‐imidated azoles in moderate to excellent yields with broad substrate scope. This reaction represents the first iron‐catalyzed C−H imidation of arene where NFSI serves as the imidation reagent, and potentially constitutes an efficient access to

  公开了一种铁（II）催化的N-氟代苯磺酰亚胺（NFSI）通过C（5）-H键裂解的恶唑和噻唑直接酰亚胺化反应，可提供中等收率到优异收率的C5咪唑，具有广泛的底物范围。该反应代表了芳烃的第一个铁催化的CH酰亚胺化，其中NFSI用作酰亚胺化试剂，并潜在地构成了对C5官能化的唑的有效利用，具有重要的医学意义。
• PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND
  申请人：FUJIFILM Corporation

  公开号：EP3604326A1

  公开（公告）日：2020-02-05

  An object of the present invention is to provide a novel cyclic peptide compound excellent in cell membrane permeability, a method for producing the same, a composition for screening use, and a method for selecting a cyclic peptide compound that binds to a target substance. According to the present invention, a peptide compound represented by Formula (1) or a salt thereof is provided. In the formula, the symbols have the meanings as defined in the specification of the present application.

  本发明的目的是提供一种细胞膜渗透性极佳的新型环肽化合物、一种生产该化合物的方法、一种用于筛选的组合物以及一种选择与目标物质结合的环肽化合物的方法。根据本发明，提供了一种由式（1）表示的多肽化合物或其盐。式中的符号具有本申请说明书中定义的含义。
• Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound
  申请人：FUJIFILM Corporation

  公开号：US11319347B2

  公开（公告）日：2022-05-03

  An object of the present invention is to provide a novel cyclic peptide compound excellent in cell membrane permeability, a method for producing the same, a composition for screening use, and a method for selecting a cyclic peptide compound that binds to a target substance. According to the present invention, a peptide compound represented by Formula (1) or a salt thereof is provided. In the formula, the symbols have the meanings as defined in the specification of the present application.

  本发明的目的是提供一种细胞膜渗透性极佳的新型环肽化合物、一种生产该化合物的方法、一种用于筛选的组合物以及一种选择与目标物质结合的环肽化合物的方法。根据本发明，提供了一种由式（1）表示的多肽化合物或其盐。式中的符号具有本申请说明书中定义的含义。